| Literature DB >> 32443983 |
Alejandra Vargas-Valderrama1,2, Antonietta Messina3,4, Maria Teresa Mitjavila-Garcia5,3, Hind Guenou5,3,6.
Abstract
Over the last 4 decades, cell culture techniques have evolved towards the creation of in vitro multicellular entities that incorporate the three-dimensional complexity of in vivo tissues and organs. As a result, stem cells and adult progenitor cells have been used to derive self-organized 3D cell aggregates that mimic the morphological and functional traits of organs in vitro. These so-called organoids were first generated from primary animal and human tissues, then human pluripotent stem cells (hPSCs) arose as a new tool for organoid generation. Due to their self-renewal capacity and differentiation potential, hPSCs are an unlimited source of cells used for organoids. Today, hPSC-derived small intestinal, kidney, brain, liver, and pancreas organoids, among others, have been produced and are promising in vitro human models for diverse applications, including fundamental research, drug development and regenerative medicine. However, achieving in vivo-like organ complexity and maturation in vitro remains a challenge. Current hPSC-derived organoids are often limited in size and developmental state, resembling embryonic or fetal organs rather than adult organs. The use of endothelial cells to vascularize hPSC-derived organoids may represent a key to ensuring oxygen and nutrient distribution in large organoids, thus contributing to the maturation of adult-like organoids through paracrine signaling.Here, we review the current state of the art regarding vascularized hPSC-derived organoids (vhPSC-Orgs). We analyze the progress achieved in the generation of organoids derived from the three primary germ layers (endoderm, mesoderm and ectoderm) exemplified by the pancreas, liver, kidneys and brain. Special attention will be given to the role of the endothelium in the organogenesis of the aforementioned organs, the sources of endothelial cells employed in vhPSC-Org protocols and the remaining challenges preventing the creation of ex vivo functional and vascularized organs.Entities:
Keywords: Brain; Endothelial cells; Kidney; Liver; Pancreas; Vascularized organoids; hPSCs
Year: 2020 PMID: 32443983 PMCID: PMC7245026 DOI: 10.1186/s12929-020-00661-y
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410
Summary of the current published protocols for vascularized hPSC-derived organoids
| Organoid | ECs | Vascularization strategy | Endothelial characterization (Phenotype) | FBS | Ex. VEGF | Commentaries | Ref |
|---|---|---|---|---|---|---|---|
| HUVEC | MSC-driven condensation on | • Endothelial networks • IF: CD31 • | + | + | Initial % EC: 36% In vivo reperfusion and non-leaky vessels | [ | |
| HUVEC | • IF: vWF | + | – | Initial % EC: 50% Final % EC: 45–50% | [ | ||
| HUVEC | MSC-driven condensation on | • Endothelial networks • IF: CD31 • | + | + | Failure of non-vascularized (in vitro Initial % EC: 11% | [ | |
| hPSC-EC | • Endothelial networks • IF and FACS: CD34, CD31 • IF: CD144, CD146 • mRNA expression: JAG1, NOTCH2, HES1 | – | – | [ | |||
| HAMEC | • Endothelial rosettes • IF: CD31+ • mRNA expression: Factor VIII, vWF and other coagulation cascade and fibrinolysis genes • | + | – | Only vascularized organoids supported a sustained production of albumin in vivo up to 14 days after transplantation. Initial % EC: 30% Initial % EC: 15% | [ | ||
| HUVEC | MSC-driven condensation on | • Endothelial networks • IF: CD31 • RNA-seq analysis • Protein analysis of the culture supernatants | + | + | Initial % EC: 45% Surface contact of HE-iPSCs with non-parenchymal cells (HUVECs and MSCs) is required for organoid morphogenesis. | [ | |
| hPSC-EC HAEC | MSC-driven condensation on | • Endothelial networks • FACS: CD34, CD31, CD144 at t0 • Proteomic analysis | + | + | Initial % EC: 40% Differences on the organoid metabolic rate and TGF-β and Wnt signaling pathways were observed depending on the source of EC and MSC used. | [ | |
| hPSC-EC | iMSC-driven condensation on | • Endothelial networks • IF: CD144, CD31 • scRNA-seq analysis • | + | + | Completely hiPSC-derived liver organoids outperformed their counterpart made of HUVEC and MSCs. Inhibition of KDR decreased the number of endothelial networks and hampered hepatocyte maturation. | [ | |
| hPSC-EC | • Endothelial networks with lumen • IF: KDR, CD31, SOX17 | – | – | [ | |||
| hPSC-EC HUVEC | • Endothelial networks with lumen • IF: KDR, CD31, CD34 • scRNA-seq analysis: Different subsets of EC • | + | – | Maximum 3% of EC at d14 | [ | ||
| hPSC-EC | • Endothelial cords around capsule and tubular structures • IF: CD31, vWF | – | – | Organoids survived for up to 2 months. | [ | ||
| hPSC-EC, HUVECS, HNDFs, and adult GMECs | From d11 to d14, organoids were culture on | • Endothelial networks with lumen • IF and FACS: CD31, MCAM and KDR • mRNA expression: CD31 | + | – | [ | ||
| hPSC-EC | • Vascular-like structures at d30; • IF: CD144, CD31, vWF, KDR and tight junctions: OCLN, αZO-1 • EM: Tight junctions • mRNA expression: CD144, CD31, KDR, TEK, vWF, OCLN, CD34, CLDN5, OCLN, TJP1, ABCB1 and GLUT1 • In vitro perfusion with Dextran-FITC. • TEER: 351 ± 10 Ω cm− 2 • scRNA-seq analysis • | + | – | EC came from modified hiPSC expressing ETV2 from day 18 of differentiation. Organoids survived up to 4 months and reached 3,5–4 mm of diameter. Vascularized organoids displayed better neural differentiation and neural functions. | [ | ||
| hPSC-EC | • Tubule-like structures • IF: CD31, vWF, CLDN5 • mRNA expression: ANGPT1, CD31 • RNA-seq analysis: 106 TJ-related genes and GPR124 | + | + | Organoids survived up to 4 months. α-SMA pericytes surrounded CD31+ EC. | [ | ||
| hPSC-EC | • IF: CD31, CD144, Z0–1 • FACS: CD31 • mRNA expression: BCRP, PGP, GLUT-1 | – | – | NPSC: EC: hMSC (1:2:3) Organoids survived up to 2 months. | [ | ||
| hPSC-EC | • Tubular structures • IF: CD31 • | + | + | Organoids survived up to 2 months. Only in vitro vascularized organoids survived in vivo 2 weeks after transplantation. | [ |
Organ, endothelial cell source, vascularization strategy, endothelial characterization, use of fetal bovine serum (FBS) and exogenous VEGF (Ex. VEGF) are described for every vhPSC-Orgs protocol. IF: Immunofluorescence. FACS: fluorescence activated cell sorting. scRNA-seq analysis: single cell RNA sequencing analysis. *For pancreas organoids, authors often refer to pancreatic islet organoids because of the missing exocrine compartment. ** Liver organoids are also known in most cases as liver buds (LB)
Fig. 1Strategies for the vascularization of hPSC-derived organoids. hPSC-derived endothelial cells (ECs) present in the vascularized organoids can be obtained by a) codifferentiation of human pluripotent stem cells (hPSCs) into all the cell lineages forming the organoid or b) independent differentiation of hPSCs into ECs and tissue progenitors for further coculture. hPSC-derived ECs can also be added to preformed organoids. PPs: pancreas progenitors; NP: nephron progenitors; NSCs: neural stem cells; LSECs: liver sinusoidal endothelial cells; and CECS: cerebral endothelial cells